Garitaonaindia Yago, Martínez-Cutillas Marta, Uribarren Maria, Redondo Isabel, Calvo Virginia, Serna-Blasco Roberto, Provencio Mariano
Medical Oncology Department, Puerta de Hierro University Hospital, C/ Manuel de Falla, 1, 28222, Majadahonda, Madrid, Spain.
Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Puerta De Hierro University Hospital, Majadahonda, Madrid, Spain.
Clin Transl Oncol. 2025 Jan 9. doi: 10.1007/s12094-024-03834-5.
This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. Several trials are ongoing, and a few have reported results, suggesting that adoptive cell therapies may represent a potential treatment option for these patients, especially when checkpoint inhibition has failed. We also discuss the potential implementation of these therapies, as they present a new toxicity profile and an intrinsic financial burden. Despite the challenges to overcome, such as the accurate identification of antigens and developing strategies to improve efficacy and toxicity profiles, new cellular therapies are experiencing significant development in the field of thoracic malignancies.
本综述旨在总结过继性细胞疗法（包括肿瘤浸润淋巴细胞、基因工程化T细胞受体和嵌合抗原受体T细胞）在治疗胸部恶性肿瘤（包括非小细胞肺癌、小细胞肺癌和恶性胸膜间皮瘤）方面的最新研究和发现。多项试验正在进行中，有几项已经报告了结果，表明过继性细胞疗法可能是这些患者的一种潜在治疗选择，尤其是在检查点抑制治疗失败时。我们还讨论了这些疗法的潜在应用，因为它们呈现出一种新的毒性特征和内在的经济负担。尽管存在需要克服的挑战，如准确识别抗原以及制定提高疗效和毒性特征的策略，但新的细胞疗法在胸部恶性肿瘤领域正经历着显著的发展。
